Li, W.; Sparidans, R.W.; Lebre, M.C.; Beijnen, J.H.; Schinkel, A.H.
ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. Pharmaceutics 2021, 13, 1761.
https://doi.org/10.3390/pharmaceutics13111761
AMA Style
Li W, Sparidans RW, Lebre MC, Beijnen JH, Schinkel AH.
ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. Pharmaceutics. 2021; 13(11):1761.
https://doi.org/10.3390/pharmaceutics13111761
Chicago/Turabian Style
Li, Wenlong, Rolf W. Sparidans, Maria C. Lebre, Jos H. Beijnen, and Alfred H. Schinkel.
2021. "ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability" Pharmaceutics 13, no. 11: 1761.
https://doi.org/10.3390/pharmaceutics13111761
APA Style
Li, W., Sparidans, R. W., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H.
(2021). ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. Pharmaceutics, 13(11), 1761.
https://doi.org/10.3390/pharmaceutics13111761